Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study

References

• Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013;382:614–623.
   PubMed Web of Science ®Google Scholar
• Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014;46:517–592.
   Google Scholar
• Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford, PJ, Valentin V, Yusuf S, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682–1687.
   PubMed Web of Science ®Google Scholar
• Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013;111:985–990.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: Insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013;73:1681–1709.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Galasso G, De Luca G, Parodi G, Antoniucci D, Esposito G, Trimarco B, Piscione F. Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: A meta-regression analysis of 30 randomized trials. Atherosclerosis 2014;234:176–184.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013;6:854–863.
   PubMed Web of Science ®Google Scholar
• Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: A systematic review and meta-analysis. J Thromb Haemost 2015;13:931–942.
   PubMed Web of Science ®Google Scholar
• Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, Möckel M, Giannitsis E, Thygesen K, ten Berg JM, et al. Platelet function testing in acute cardiac care - is there a role for prediction for prevention of stent thrombosis and bleeding? Thromb Haemost 2015;113:221–230.
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145–1152.
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259–274.
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–2109.
   PubMed Web of Science ®Google Scholar
• Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013;109:817–824
   PubMed Web of Science ®Google Scholar
• Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010;160:543–551.
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013;61:872–879.
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474–2483.
   PubMed Web of Science ®Google Scholar
• Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets 2013;24:528–537.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, et al. Variability of individual platelet reactivity over time in patients treated with clopidogrel: Insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol 2014;64:361–368.
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011;22:579–587.
   PubMed Web of Science ®Google Scholar
• Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RP. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: A post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther 2013;18:555–559.
   PubMed Web of Science ®Google Scholar
• Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006;95:652–658.
   PubMed Web of Science ®Google Scholar
• Würtz M, Hvas AM, Jensen LO, Kaltoft AK, Tilsted HH, Kristensen SD, Grove EL. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014;175:274–279.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar